Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
Identifieur interne : 002B17 ( PubMed/Curation ); précédent : 002B16; suivant : 002B18Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
Auteurs : Samay Jain [États-Unis] ; Paul E. Greene ; Steven J. FruchtSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Tetrabenazine.
- drug therapy : Hyperkinesis.
- Adolescent, Child, Child, Preschool, Dose-Response Relationship, Drug, Drug Tolerance, Female, Follow-Up Studies, Humans, Infant, Male, Pediatrics, Retrospective Studies.
Abstract
Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.
DOI: 10.1002/mds.21063
PubMed: 16958131
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B17
Links to Exploration step
pubmed:16958131Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tetrabenazine therapy of pediatric hyperkinetic movement disorders.</title><author><name sortKey="Jain, Samay" sort="Jain, Samay" uniqKey="Jain S" first="Samay" last="Jain">Samay Jain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. jains@upmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E" last="Greene">Paul E. Greene</name></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21063</idno><idno type="RBID">pubmed:16958131</idno><idno type="pmid">16958131</idno><idno type="wicri:Area/PubMed/Corpus">002B17</idno><idno type="wicri:Area/PubMed/Curation">002B17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tetrabenazine therapy of pediatric hyperkinetic movement disorders.</title><author><name sortKey="Jain, Samay" sort="Jain, Samay" uniqKey="Jain S" first="Samay" last="Jain">Samay Jain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. jains@upmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea></affiliation></author><author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E" last="Greene">Paul E. Greene</name></author><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Dose-Response Relationship, Drug</term><term>Drug Tolerance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Hyperkinesis (drug therapy)</term><term>Infant</term><term>Male</term><term>Pediatrics</term><term>Retrospective Studies</term><term>Tetrabenazine (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Tetrabenazine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hyperkinesis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Dose-Response Relationship, Drug</term><term>Drug Tolerance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Infant</term><term>Male</term><term>Pediatrics</term><term>Retrospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16958131</PMID><DateCreated><Year>2006</Year><Month>12</Month><Day>05</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Tetrabenazine therapy of pediatric hyperkinetic movement disorders.</ArticleTitle><Pagination><MedlinePgn>1966-72</MedlinePgn></Pagination><Abstract><AbstractText>Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Samay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. jains@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Frucht</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018726">Anti-Dyskinesia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z9O08YRN8O</RegistryNumber><NameOfSubstance UI="D013747">Tetrabenazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018726">Anti-Dyskinesia Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004361">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006948">Hyperkinesis</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010372">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013747">Tetrabenazine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21063</ArticleId><ArticleId IdType="pubmed">16958131</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002B17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16958131
|texte= Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16958131" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |